JARDIANCE under the microscope: Real-World safety check for korean kidney patients

NCT ID NCT06287073

Completed Knowledge-focused Sponsor: Boehringer Ingelheim Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This completed study looked at the safety of the diabetes drug JARDIANCE (empagliflozin) in 299 Korean adults with chronic kidney disease. Researchers tracked side effects and measured changes in a key kidney health marker (urine albumin-creatinine ratio) after 12 and 24 weeks of treatment. The goal was to see how well the drug works and how safe it is in routine medical practice.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Empagliflozin (JARDIANCE)
What this could lead to: If results are positive, this could confirm that JARDIANCE is safe and effective for Korean patients with chronic kidney disease in everyday practice.
What could go wrong: This is an observational study, not a controlled trial, so it cannot prove cause and effect. Results may not apply to other populations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for KIDNEY DISEASE, CHRONIC are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic kidney disease chronic renal failure syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

KIDNEY DISEASE, CHRONIC

Contacts and locations

Locations

Chonnam National University Hospital

Gwangju, 61469, South Korea
Chungbuk National University Hospital

Cheongiu, 28644, South Korea
Hallym University Sacred Heart Hospital

Anyang, 07441, South Korea
Inje University Ilsan Paik Hospital

Goyang, 10380, South Korea
Korea University Anam Hospital

Seoul, 02841, South Korea
Samsung Medical Center

Seoul, 06351, South Korea
Seoul National University Hospital

Seoul, 03080, South Korea
Soonchunhyang University Hospital Seoul

Seoul, 04401, South Korea
The Catholic University of Korea, Eunpyeong St. Mary's Hospital

Seoul, 03312, South Korea
The Catholic University of Korea, Yeouido St.Mary's Hospital

Seoul, 07345, South Korea
Ulsan University Hospital

Ulsan, 44033, South Korea
Yonsei University Wonju Severance Christian Hospital

Gangwon, 26426, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.